Evaluation of HLA-Haplotype Disparate Parental Marrow Grafts
Depleted of T Lymphocytes by Differential Agglutination with a
Soybean Lectin and E-Rosette Depletion for the Treatment of
Severe Combined Immunodeficiency

Reisner, Y.; O'Reilly, R.J.; Brochstein, J.; Collins, N.; Keever, C.; Kapoor, N.; Kirkpatrick, D.; Kernan, N.; Dupont, B.; Burns, J.

doi:10.1159/000461564

Vox Sanguinis

1986

DOI: 10.1159/000461564

|View full text |Cite

Evaluation of HLA-Haplotype Disparate Parental Marrow Grafts Depleted of T Lymphocytes by Differential Agglutination with a Soybean Lectin and E-Rosette Depletion for the Treatment of Severe Combined Immunodeficiency

Y. Reisner¹,

R.J. O'Reilly²,

J. Brochstein³

et al.

Abstract: The factors that impact upon successful bone marrow transplantation leading to immunologic reconstitution in severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome, and in other lethal congenital immunodeficiencies are reviewed. Evidence is presented that graft-versus-host disease (GVHD) can be abrogated by the depletion of T cells, even from histoincompatible marrow grafts. However, graft resistance or restricted immune reconstitution has been observed with significant frequency. The bases for T c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2019

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications

Hönig

Albert

Schulz

et al. 2006

Blood

View full text Add to dashboard Cite

Adenosine deaminase (ADA) deficiency is a systemic metabolic disease that causes an autosomal recessive variant of severe combined immunodeficiency (SCID) and less consistently other complications including neurologic abnormalities. Hematopoietic stem cell transplantation (HSCT) is able to correct the immunodeficiency, whereas control of nonimmunologic complications has not been extensively explored. We applied HSCT in 15 ADA-deficient patients consecutively treated at our institutions since 1982 and analyzed long-term outcome.

show abstract

Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications

Hönig

Albert

Schulz

et al. 2006

Blood

View full text Add to dashboard Cite

show abstract

The Evolution of T Cell Depleted Haploidentical Transplantation

et al. 2019

View full text Add to dashboard Cite

Work on bone marrow transplantation from haploidentical donor has been proceeding for over 20 years all over the world and new transplant procedures have been developed. To control both graft rejection and graft vs. host disease, some centers have preferred to enhance the intensity of the conditioning regimens and the post-transplant immune suppression in the absence of graft manipulation; others have concentrated on manipulating the graft in the absence of any additional post-transplant immune suppressive agent. Due to the current high engraftment rates, the low incidence of graft-vs.-host disease and regimen related mortality, transplantation from haploidentical donors have been progressively offered even to elderly patients. Overall, survivals compare favorably with reports on transplants from unrelated donors. Further improvements will come with successful implementation of strategies to enhance post-transplant immune reconstitution and to prevent leukemia relapse.

show abstract

Haematopoietic Graft Engineering

Hwang

2004

Ann Acad Med Singap

View full text Add to dashboard Cite

Although haematopoietic stem cell transplantation (HSCT) is a powerful treatment modality, it is a blunt instrument against cancer and diseases of the haematopoietic and immune system. Various techniques have been developed to engineer the haematopoietic stem cell (HSC) graft to enable it to perform its task more effectively. These techniques include the removal of cells which cause graft-versus-host disease (GVHD), the eradication of cells which might cause relapse, the expansion of donor cells when there is an inadequate cell dose, and the addition of selected cells to improve graft function. In this review, we will discuss each of these means of haematopoietic graft manipulation in turn and then touch on some regulatory requirements in the field of haematopoietic graft engineering. While the science is still prepubescent, it has passed its infancy and further developments in the next decade or so should allow it to be taken to a wider scale to benefit more patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluation of HLA-Haplotype Disparate Parental Marrow Grafts Depleted of T Lymphocytes by Differential Agglutination with a Soybean Lectin and E-Rosette Depletion for the Treatment of Severe Combined Immunodeficiency

Cited by 3 publications

References 19 publications

Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications

Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications

The Evolution of T Cell Depleted Haploidentical Transplantation

Haematopoietic Graft Engineering

Contact Info

Product

Resources

About